Navigation Links
BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
Date:3/8/2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," says David E. Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH) and a co-corresponding author of the Cancer Cell paper. "While current BRAF inhibitor treatment is a major improvement shrinking tumors in most patients and extending survival for several months patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

In about half the cases of malignant melanoma the most deadly form of skin cancer tumor growth is driven by mutations in the BRAF gene. Research by investigators at the MGH Cancer Center and elsewhere has shown that treatment with drugs that block BRAF activity temporarily halts tumor growth. Combining a BRAF inhibitor with a drug that targets MEK, another protein in the same growth pathway, strengthens and extends the antitumor response. The current study was designed to investigate how BRAF inhibition changes metabolic activity within melanoma cells and to find other possible treatment targets.

The most common way that cells convert glucose into energy is called oxidative phosphorylation and largely relies on the activity of the cellular structures called mitochondria. Many cancer cells use an alternative mechanism that produces the energy compound ATP without involving mitochondria. A series of experiments by the MGH team revealed that the elevated BRAF activity in BRAF-positive melanoma cells suppresses oxidative phosphorylation by reducing expression of a transcription factor called MITF. Suppressing production of MITF reduced levels of a protein called PGC1α that regulates the generation and function of mitochondria. But melanoma cells treated with a BRAF inhibitor showed elevated MITF activity, along with increased expression of oxidative phosphorylation genes and greater numbers of mitochondria. By switching to oxidative phosphorylation to supply the energy they need, the tumor cells increased their ability to survive in spite of BRAF inhibitor treatment.

"These findings suggest that combination treatment with mitochondrial inhibitors could improve the efficacy of BRAF inhibitors in malignant melanoma," says Fisher, the Wigglesworth Professor of Dermatology at Harvard Medical School. "Several small molecules that target mitochondrial metabolism have been identified by investigators here at the MGH and elsewhere, and laboratory investigations of specific combinations of BRAF inhibitors with mitochondrial antagonists are currently underway."


'/>"/>

Contact: Michelle Marcella
mmarcella@partners.org
617-724-2755
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
2. VyGone Inhibitor Zapper: The Brand New Solution For the Safe Treatment Of Sores, Warts and Herpes
3. Inhibitors of shuttle molecule show promise in acute leukemia
4. Leukemia inhibitory factor may be a promising target against pancreatic cancer
5. Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy
6. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
7. PARP inhibitors may have clinical utility in HER2-positive breast cancers
8. New mechanism of action for PARP inhibitors discovered
9. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
10. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
11. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland ... to 3 pm to present to graduate students exciting new and innovative hope research ... project led by The Health Improvement Service of the Western Health & Social Care ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... and personal financial planning to families and business owners in North Central West ... to help provide services to differently abled residents in the region. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... Branches, Inc. has been partnering ... in grant funding to support its programs focused on providing opportunity to low-income families ... a grant by the Foundation of $15,000 to support its , Climb to College ...
(Date:6/22/2017)... IN (PRWEB) , ... June 22, 2017 , ... ... benefits advisory organization, is pleased to welcome Whipple & Company as its newest ... the clear purpose of balancing their clients’ risk while tailoring optimized benefit packages ...
Breaking Medicine News(10 mins):
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is recognized ... excellence as a Podiatrist in Alabama . ... Family First Foot Care. He brings over 20 years of experience, ... management and healthcare, to his role. ... Care, PC is pleased to welcome you to his ...
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... DUBLIN , June 7, 2017 Endo ... on June 7, 2017, the Hon. Joseph R. ... District of West Virginia , entered ... Systems, Inc. Pelvic Repair System Products Liability Litigation (the ... filed MDL cases to provide expert disclosures on specific ...
Breaking Medicine Technology: